Development and validation of a risk scoring model to predict net adverse cardiovascular outcomes after primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: Rationale and design of the RISK-PCI study

Journal of Interventional Cardiology

Volumn 22, Issue 4, 2009, Pages 320-328

  Mrdovic, Igor ^a   Savic, Lidija ^a   Perunicic, Jovan ^a   Asanin, Milika ^a   Lasica, Ratko ^a   Marinkovic, Jelena ^c   Vasiljevic, Zorana ^a   Ostojic, Miodrag ^b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b Cardiology Clinic   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENOXAPARIN; HEPARIN; INOTROPIC AGENT; PANTOPRAZOLE; RANITIDINE; TIROFIBAN; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; ST SEGMENT ELEVATION; ANALOGS AND DERIVATIVES; CORONARY ARTERY DISEASE; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; STATISTICAL MODEL; THEORETICAL MODEL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VALIDATION STUDY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MODELS, STATISTICAL; MODELS, THEORETICAL; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION INHIBITORS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TICLOPIDINE; TREATMENT OUTCOME; ANGIOPLASTY, BALLOON, CORONARY; KAPLAN-MEIER ESTIMATE;

EID: 68849084835     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2009.00476.x     Document Type: Article

References (35)

1. Spencer FA, Moscucci M, Granger CB, et al. for the GRACE Investigators. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation 2007 116 : 2793 2801.
2. King SB, Smith SC, Hirshfeld JW Jr., et al. [2007 writing group to review new evidence and update the ACC-AHA-SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 writing committee]. 2007 focused update of the ACC-AHA-SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology-American Heart Association. Task force on practice guidelines. Circulation 2008 117 : 261 295.
3. Antman EA, Hand M, Armstrong PW, et al. [2007 writing group to review new evidence and update the ACC-AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 writing committee]. 2007 focused update of the ACC-AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. A report of the American College of Cardiology-American Heart Association. Task force on practice guidelines. Circulation 2008 117 : 296 329.
4. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005 26 : 804 847.
5. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005 3 : 692 694.
6. Honda Y, Fitzgerald PJ. Stent thrombosis: An issue revisited in a changing world. Circulation 2003 108 : 2 5.
7. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes. An analysis from the ACUITY trial. J Am Coll Cardiol 2007 49 : 1362 1368.
8. Bassand JP. Bleeding and transfusion in acute coronary syndromes: A shift in the paradigm. Heart 2008 94 : 661 666.
9. Buresly K, Eisenberg MJ, Zhang X, et al. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 2005 165 : 784 789.
10. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006 114 : 774 782.
11. Moscucci M, Fox KAA, Cannon CP, et al. for the GRACE Investigators. Predictors of major bleeding in acute coronary syndromes: The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003 24 : 1815 1823.
12. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb-IIIa inhibitors in acute coronary syndromes; a meta-analysis of all major randomised clinical trials. Lancet 2002 359 : 189 198. (Pubitemid 34113814)
13. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapyand platelet glycoprotein IIb-IIIa inhibition: The GUSTO V randomised trial. Lancet 2001 357 : 1905 1914.
14. Rao SV, O'Grady K, Pieper KS, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006 47 : 809 816.
15. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003 92 : 930 935.
16. Rao SV, Jollis JG, Harrington RA, et al. Califf RM: Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004 292 : 1555 1562.
17. Morrow DA, Antman EM, Charlesworth A, et al. TIMI Risk Score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation. Circulation 2000 102 : 2031 2037.
18. Jacobs DR Jr., Kroenke C, Crow R, et al. PREDICT: A simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: The Minnesota Heart Survey. Circulation 1999 100 : 599 607.
19. Singh M, Reeder GS, Jacobsen SJ, et al. Scores for post-myocardial infarction risk stratification in the community. Circulation 2002 106 : 2309 2314.
20. Addala S, Grines CL, Dixon SR, et al. Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score). Am J Cardiol 2004 93 : 629 632.
21. De Luca G, Suryapranata H, Arnoud WJ, et al. Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: Implications for early discharge. Circulation 2004 109 : 2737 2743. (Pubitemid 38737921)
22. Negassa A, Monrad S, Bang JY, et al. Tree-structured risk stratification of in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction: A report from the New York State percutaneous coronary intervention database. Am Heart J 2007 154 : 322 329.
23. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial - Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988 11 : 1 11.
24. Valgimigli M, Campo G, Percoco G, et al. for the multicentre evaluation of single high-dose bolus tirofiban vs. abciximab with sirolimus-eluting stent or bare-metal stent in acute myocardial infarction study (MULTISTRATEGY) Investigators. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction. The MULTISTRATEGY randomized trial. JAMA 2008 299 : 1788 1799.
25. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study. JAMA 2005 294 : 1224 1232.
26. Stone GW, Witzenbichler B, Guagliumi G, et al. for the HORIZONS-AMI trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. NEJM 2008 358 : 2218 2230.
27. Mehilli J. Pretreatment With a High Loading Dose of Clopidogrel and Value of Abciximab During Primary Coronary Intervention in Patients With Acute Myocardial Infarction: Results of the Randomized BRAVE-3 Trial. SCAI-ACC i2 Summit-American College of Cardiology Annual Scientific Session, Chicago, IL, March-April 2008.
28. Fresco C, Carinci F, Maggioni AP, et al. Very early assessment of risk for in-hospital death among 11,483 patients with acute myocardial infarction GISSI Investigators. Am Heart J 1999 138 : 1058 1064.
29. Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: The CADILLAC Risk Score. J Am Coll Cardiol 2005 45 : 1397 1405. (Pubitemid 40615609)
30. Lev EI, Kornowski R, Vaknin-Assa H, et al. Comparison of the predictive value of four different risk scores for outcomes of patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2008 102 : 6 11.
31. May MRL, Wells GA, Labinaz M, et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol 2005 46 : 417 424.
32. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005 294 : 3108 3116.
33. Valente S, Lazzeri C, Salvadori C, et al. Effectiveness and safety of routine primary angioplasty in patients aged ≥ 85 years with acute myocardial infarction. Circ J 2008 72 : 67 70.
34. Mehta SR, Yusuf S, Peters RJ, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001 358 : 527 533.
35. Nikolsky E, Mehran R, Dangas G, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007 28 : 1936 1945.